Kadmon Holdings, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kadmon Holdings, Inc. (KDMN) is a biopharmaceutical company that discovers, develops, and commercializes small molecules and biologics for unmet medical needs in immunology, fibrosis, and oncology; its lead product is Rezurock (belumosudil), a Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitor approved by the FDA for the treatment of chronic graft-versus-host disease in adult and pediatric patients one year and older after failure of at least two systemic therapies. Founded in 2010 and headquartered in New York City with additional operations in Warrendale, Pennsylvania, the company previously marketed branded generic ribavirin products for chronic hepatitis C virus infection. In November 2021, Sanofi completed its $1.9 billion acquisition of Kadmon Holdings, integrating it as Kadmon, a Sanofi Company, to bolster its transplant portfolio while later closing Kadmon's New York facility to streamline operations. Kadmon advances Rezurock in ongoing clinical trials for diffuse cutaneous systemic sclerosis and continues to target therapies for immune-mediated diseases, operating primarily in the United States.
Sanofi completes acquisition of Kadmon
Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results
3 Biotech Stocks That Surged in September
Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting
SHAREHOLDER ALERT: WeissLaw LLP Reminds CXP, JMP, ECHO, and KDMN Shareholders About Its Ongoing Investigations
3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health
KADMON HOLDINGS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GTS, HRC, JMP, KDMN, FIBK; Shareholders are Encouraged to Contact the Firm
SHAREHOLDER ALERT: WeissLaw LLP Reminds ECHO, KDMN, HRC, and DVCR Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Kadmon Holdings, Inc. - KDMN
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kadmon Holdings, Inc.
Kadmon, The Big Short
Kadmon Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Kadmon Holdings, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – KDMN
KDMN Stock: Why It Surged Today
Shareholder Alert: Ademi LLP investigates whether Kadmon Holdings, Inc. has obtained a Fair Price in its transaction with Sanofi
Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock
Why Kadmon Holdings Stock Is Rocketing Higher Today
Sanofi to acquire Kadmon to further strengthen growth of transplant business
Kadmon Stock Soars as Sanofi Buys U.S. Biotech for $1.9 Billion
Sanofi's $1.9 Billion Bet On Kadmon: What You Need to Know